Test Code DIPGS Diphtheria Toxoid IgG Antibody, Serum
Reporting Name
Diphtheria Toxoid IgG Ab, SUseful For
Determining a patient's immunological response to diphtheria toxoid vaccination
Aiding in the evaluation of immunodeficiency
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 30 days | |
Frozen | 30 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat inactivated specimen | Reject |
Reference Values
Vaccinated: Positive (≥0.01 IU/mL)
Unvaccinated: Negative (<0.01 IU/mL)
Reference values apply to all ages.
Day(s) Performed
Monday through Friday
CPT Code Information
86317
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DIPGS | Diphtheria Toxoid IgG Ab, S | 48654-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
DIPG | Diphtheria IgG Ab | 45166-6 |
DEXDP | Diphtheria IgG Value | 48654-8 |
Clinical Information
Diphtheria is an acute, contagious, febrile illness caused by the bacterium Corynebacterium diphtheriae. The disease is classically characterized by a combination of localized inflammation in the upper respiratory tract with the formation of a diphtheric pseudomembrane over the oropharynx, including the tonsils, pharynx, larynx, and posterior nasal passages. C diphtheriae produces a potent diphtheria exotoxin that is absorbed systemically and can lead to cardiac failure and paralysis of the diaphragm.
The disease is preventable by vaccination with diphtheria toxoid, which stimulates antidiphtheria toxoid antibodies. In the United States, diphtheria toxoid is administered to children as part of the combined diphtheria, tetanus, and acellular pertussis (TDaP) vaccine. A patient's immunological response to diphtheria toxoid vaccination can be determined by measuring antidiphtheria toxoid IgG antibody using this enzyme immunoassay technique. An absence of antibody formation postvaccination may relate to immune deficiency disorders, either congenital or acquired, or iatrogenic due to immunosuppressive drugs.
Interpretation
Results of 0.01 IU/mL or more suggest a vaccine response.
A diphtheria toxoid booster should be considered for patients with antidiphtheria toxoid IgG values between 0.01 and less than 0.1 IU/mL.
Cautions
This assay does not provide diagnostic proof of lack of protection against diphtheria or the presence of absence of immunodeficiency. Results must be confirmed by clinical findings and other serological tests.
Supportive Data
A total of 211 serum samples prospectively submitted to our reference laboratory for routine testing for antidiphtheria toxoid IgG antibodies by the Binding Site Anti-Diphtheria Toxoid IgG enzyme-linked immunosorbent assay (ELISA) were also evaluated by the EuroImmun Anti-Diphtheria Toxoid IgG ELISA and results are summarized in the table:
Table. Comparison of the EuroImmun and Binding Site Anti-Diphtheria Toxoid IgG ELISAs
|
Binding Site IgG ELISA |
|
||
Positive |
Negative |
Total |
||
EuroImmun IgG ELISA |
Positive |
206 |
0 |
206 |
Negative |
4(a) |
1 |
5 |
|
|
Total |
210 |
1 |
211 |
a) 1 of 4 samples tested positive by the ARUP Quantitative Multiplex Bead assay for antidiphtheria toxoid IgG
% Positive Agreement: 98.1% (206/210); 95% CI: 95.0-99.4%
% Negative Agreement: 100% (1/1); 95% CI: 16.8-100%
% Overall Agreement: 98.1% (207/211); 95% CI: 95.1-99.4%
Clinical Reference
1. Centers for Disease Control and Prevention (CDC); National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Diphtheria. CDC; Updated September 9, 2022. Accessed September 5, 2024. Available at www.cdc.gov/diphtheria/index.html
2. Truelove SA, Keegan LT, Moss WJ, et al. Clinical and epidemiological aspects of diphtheria: a systematic review and pooled analysis. Clin Infect Dis. 2020;71(1):89-97
Method Description
The Anti-Diphtheria Toxoid IgG enzyme-linked immunosorbent assay provides a quantitative in vitro assay for detecting human IgG-class antibodies to diphtheria toxoid. The test kit contains reagent wells coated with diphtheria toxoid. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labeled antihuman IgG (enzyme conjugate), catalyzing a color reaction.(Unpublished Mayo method)
Report Available
Same day/1 to 4 daysSpecimen Retention Time
14 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.